Literature DB >> 3475775

Characterization of specific immune complexes in HIV-related disorders.

C Carini, I Mezzaroma, G Scano, R D'Amelio, P Matricardi, F Aiuti.   

Abstract

Eighty-seven seropositive subjects with HIV (human immunodeficiency virus) infection together with 20 normal controls with no history of any illness were investigated for the presence of circulating immune complexes (CIC) by the conglutinin binding assay (KgBA) and further studied for isotype characterization of CIC. Six out of 87 patients showing very high values for immune complexes (CIC) were studied for the presence of free antigen. In 3 out of 6 (1, IVc1; 1, III; 1, IVa) we could detect by ultracentrifugation analysis the presence of specific HIV (p15) anti-HIV (anti-p15) and gp41-anti-gp41 CIC. Evidence in favour of this finding is supported by: the presence of specific CIC (p15-anti-p15 or gp41-anti-gp41) seen only at pH 7.2; the apparent presence of free antigen and specific HIV antibodies were only at pH 4.0. The relevance of this finding lies in the attempt to explain the occurrence of false seronegativity seen occasionally in symptomatic patients. Thus, the presence of CIC might perhaps interfere in the routine assay (i.e. ELISA) making the diagnosis difficult. All these considerations will have to be taken into account in the future handling of this disease.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3475775     DOI: 10.1111/j.1365-3083.1987.tb02230.x

Source DB:  PubMed          Journal:  Scand J Immunol        ISSN: 0300-9475            Impact factor:   3.487


  6 in total

Review 1.  HIV-associated immune complex kidney disease.

Authors:  Ehsan Nobakht; Scott D Cohen; Avi Z Rosenberg; Paul L Kimmel
Journal:  Nat Rev Nephrol       Date:  2016-01-19       Impact factor: 28.314

2.  Antibodies against the major core protein p24 of human immunodeficiency virus: relation to immunological, clinical and prognostic findings.

Authors:  B O Lindhardt; J Gerstoft; B Hofmann; G Pallesen; L Mathiesen; E Dickmeiss; K Ulrich
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-07       Impact factor: 3.267

3.  Alpha interferon (2b) in combination with zidovudine for the treatment of presymptomatic feline leukemia virus-induced immunodeficiency syndrome.

Authors:  N S Zeidner; M H Myles; C K Mathiason-DuBard; M J Dreitz; J I Mullins; E A Hoover
Journal:  Antimicrob Agents Chemother       Date:  1990-09       Impact factor: 5.191

4.  Occurrence of polymeric IgA1 rheumatoid factor in the acquired immune deficiency syndrome.

Authors:  S Jackson; A Tarkowski; J E Collins; L M Dawson; R E Schrohenloher; D P Kotler; W J Koopman
Journal:  J Clin Immunol       Date:  1988-09       Impact factor: 8.317

5.  B cell activation and human immunodeficiency virus infection. V. Phenotypic and functional alterations in CD5+ and CD5- B cell subsets.

Authors:  S Indraccolo; M Mion; R Zamarchi; A Veronesi; M L Veronese; M Panozzo; C Betterle; A Barelli; A Borri; A Amadori
Journal:  J Clin Immunol       Date:  1993-11       Impact factor: 8.317

6.  Evidence for activation of complement in patients with AIDS related complex (ARC) and/or lymphoadenopathy syndrome (LAS).

Authors:  R Perricone; L Fontana; C de Carolis; C Carini; M C Sirianni; F Aiuti
Journal:  Clin Exp Immunol       Date:  1987-12       Impact factor: 4.330

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.